JUBLPHARMA vs PGHL: Stock Comparison

Jubilant Pharmova Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings

Jubilant Pharmova Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Jubilant Pharmova Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, JUBLPHARMA is more favourable on 1 of 13 scored metrics and PGHL on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
JUBLPHARMA is the larger company
₹15,512 Cr vs ₹11,172 Cr
P/E Ratio
PGHL has a lower P/E
34.28x vs 39.79x
P/B Ratio
JUBLPHARMA has a lower P/B
2.24x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹25.05
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.52%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs 18.7%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs -22.4%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs 18.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricJUBLPHARMAPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricJUBLPHARMAPGHL
Live Price₹989.7₹6,737
Day Change-1.8%-0.63%
Volume91,0184,611
52-Week High₹1,248₹6,975
52-Week Low₹786.05₹4,707
Distance from 52W High-20.7%-3.41%

Valuation

MetricJUBLPHARMAPGHL
Market Cap₹15,512 Cr₹11,172 Cr
P/E Ratio39.79x34.28x
P/B Ratio2.24x21.36x
EPS₹25.05₹196.64
Book Value₹448.5₹316.01
Dividend Yield0.52%2.34%

Growth

MetricJUBLPHARMAPGHL
Revenue Growth (TTM YoY)18.7%19.1%
EPS Growth (TTM YoY)-22.4%54.6%
Qtr Sales Growth18.7%19.1%
Qtr Profit Growth-17.4%54.6%

Profitability & Leverage

MetricJUBLPHARMAPGHL
ROE6.55%61.6%
ROCE8.99%83.5%
Net Margin5.28%23.22%
Operating Margin15.2%32.4%
Debt to Equity0.51x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricJUBLPHARMAPGHL
Promoter Holding44.39%0%
FII Holding15.9% 0.06 pp6.33% 0.13 pp
DII Holding11.62% 0.4 pp12.44% 1.23 pp
Public Holding24.24% 0.33 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Jubilant Pharmova Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.